IDegAsp is therefore particularly useful for patients who struggle to adhere to complex multidrug regimens or regimens requiring multiple daily injections, those requiring flexibility in the timing of insulin dosing, those failing to achieve glycaemic control despite optimising current non-insulin therapies, or with a PPG spike, with basal or premixed insulins despite successful titration to FPG target, and those at increased risk of hypoglycaemia. The gene discussed is INS; the disease is Hypoglycemia.